PIRAMAL PHARMA
|
The Current P/E Ratio of PIRAMAL PHARMA is -70.34.
| Share Price | ₹196.5 | Oct 12,2026 |
| Market Cap | ₹26,153.4 Cr | |
| Earnings-TTM | ₹-371.8 Cr | TTM-Consolidated Results |
| Price/Earnings | -70.34x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of PIRAMAL PHARMA
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹26,153.4 Cr] as on Oct 12,2026
(/) Earnings [ ₹-371.8 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ -70.34x ]
Thus, for PIRAMAL PHARMA , the investors are currently willing to pay -70.34 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of PIRAMAL PHARMA !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of PIRAMAL PHARMA over the last five years.
Historical PE (Price/Earnings) ratio chart of PIRAMAL PHARMA
PE Ratio Performance Analysis for PIRAMAL PHARMA
- PIRAMAL PHARMA 's p/e ratio for fiscal years ending Mar2026 to Mar2022 averaged 245.53x.
- PIRAMAL PHARMA 's operated at median p/e ratio of 0x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, PIRAMAL PHARMA 's p/e ratio peaked in Mar2024 at 956.95x.
- PIRAMAL PHARMA 's p/e ratio hit its five-year low in Mar2026 of -55.56x.
How does PIRAMAL PHARMA 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| PIRAMAL PHARMA | -371.81 | -70.34 | 26,153.4 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 12,172.70 | 34.67 | 422,067.0 |
| DIVIS LABORATORIES LTD | 2,925.00 | 85.12 | 248,983.0 |
| TORRENT PHARMACEUTICALS LTD | 2,156.00 | 82.55 | 177,974.0 |
| CIPLA LTD | 3,364.84 | 31.54 | 106,130.0 |
| DR REDDYS LABORATORIES LTD | 3,169.30 | 32.41 | 102,707.0 |
| MANKIND PHARMA LTD | 2,055.11 | 48.22 | 99,089.5 |
| LUPIN LTD | 5,551.01 | 16.03 | 88,988.6 |
| ZYDUS LIFESCIENCES LTD | 4,492.20 | 25.29 | 113,616.0 |
| AUROBINDO PHARMA LTD | 3,712.74 | 26.39 | 97,972.5 |
| LAURUS LABS LTD | 1,090.76 | 102.59 | 111,899.0 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs PIRAMAL PHARMA 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | -70.34x |
| Max industry PE | 102.59x |
| Median industry PE | 32.41x |
| Average industry PE | 37.68x |
You may also like the below Video Courses